SIS
PPBT

Sound Income Strategies’s Purple Biotech PPBT Stock Holding History

Sound Income Strategies’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$41 – 1471
2024
Q2 		$41 Hold
1
– – ﹤0.01% 1343
2024
Q1 		$67 Hold
1
– – ﹤0.01% 1310
2023
Q4 		$78 Buy
+1
New +$221 ﹤0.01% 1284

Other funds holding PPBT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return

Sound Income Strategies's PPBT Position: Q3 2024 in Review

Sound Income Strategies sold out of Purple Biotech (PPBT) in Q3 2024, closing a stake of 1 share — an estimated $41 sold.

Sound Income Strategies first reported a position in PPBT in Q4 2023 and held it in 3 quarters. The position peaked at $78 in Q4 2023. 10 funds tracked by Wall St. Rank hold PPBT as of Q3 2024.

  • Sound Income Strategies reported no remaining Purple Biotech position as of Q3 2024 after selling out during the quarter.
  • Sound Income Strategies sold 1 Purple Biotech share in Q3 2024, an estimated $41.
  • Sound Income Strategies first reported a position in Purple Biotech in Q4 2023 and held it in 3 quarters.
  • Sound Income Strategies's Purple Biotech position peaked at $78 in Q4 2023.
  • 10 funds tracked by Wall St. Rank held Purple Biotech as of Q3 2024.

Based on Sound Income Strategies's 13F filing for Q3 2024, filed 10 Oct 2024.